ZURICH (dpa-AFX Broker) - The major Swiss bank UBS has lowered its target price for Merck KGaA from 186 to 178 euros, but left its rating at "Buy". "There is life after Xevinapant," wrote analyst Matthew Weston on Tuesday evening with a view to the research failure of the cancer drug. He has now removed it from his valuation model for the Darmstadt-based company. He was satisfied with the healthcare sector as a "slow-growth cash machine"./ag/tih

Publication of the original study: 09.07.2024 / 18:56 / GMT

First dissemination of the original study: 10.07.2024 / 18:56 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------